All In MedTech

Device Trial Radar · NCT06102980

Endoscopic Ultrasound Shear Wave for Liver Fibrosis in MASLD Patients: The RUMIPAMBA Trial

Estimation of Liver Fibrosis in Patients With MASLD Screening Criteria Through Endoscopic Ultrasound-guided Shear Wave vs Transabdominal Ultrasound and Transient Elastography: The RUMIPAMBA Diagnostic Trial

Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 1, 2023

Primary completion

Dec 1, 2024

Study completion Apr 1, 2025

Sponsor

Lead sponsor
Instituto Ecuatoriano de Enfermedades DigestivasAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 26, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Currently, there is no description of the contribution of the endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) when describing liver fibrosis in patients with screening criteria of metabolic dysfunction-associated steatotic liver disease (MASLD), with absent-to-mild liver fibrosis. Similar research has been published but using vibration-controlled transient elastography (VCTE), recommended mainly due to its lower cost and less invasiveness. However, VCTE is limited to the anatomical proportions of the patient's body, and cannot assess the right hepatic lobe with less reliability, contrary to the EUS-SWE.

Conditions

  • Liver Steatosis
  • Fibrosis, Liver

Interventions

  • Transparietal ultrasound (US)-based shear wave elastography (SWE) attenuation measurementDevice

    The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.

  • Transparietal ultrasound (US)-based shear wave elastography (SWE) stiffness measurementDevice

    The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.

  • Vibration-controlled transient elastography (VCTE) attenuation measurementDevice

    The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.

  • Vibration-controlled transient elastography (VCTE) stiffness measurementDevice

    The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.

  • Endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) stiffness measurementDevice

    EUS-SWE will be performed by an experienced endoscopist, blinded to clinical records. The expert will use the ArrietaTM 850 EUS console (Fujifilm, Tokyo, Japan) using a linear ultrasound video gastroscope EUS-J10 (Pentax Medical, Hoya Corp, Japan). Both lobes will be evaluated. The transducer will be positioned in the gastric window to visualize right liver segment number five and left liver segment two or three. The elastogram region of interest (ROI) will be placed within the liver tissue at a distance ≥10 mm beneath the hepatic capsule in an area free of vessels and artefacts. A 10-mm circular ROI will be placed within the elastogram at a depth of 4-5 cm from the skin, and a minimum of ten successful kilopascal measurements will be obtained. In the first stage of this research, the EUS-SWE measurement will be limited to the estimation of liver fibrosis only. Currently, available EUS-SWE equipment does not allow the estimation of the attenuation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Vibration-controlled transient elastography (VCTE) liver steatosis gradeTime frame: Six months
  2. Transparietal ultrasound (US)-based shear wave elastography (SWE) liver steatosis gradeTime frame: Six months
  3. Endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) liver steatosis gradeTime frame: Six months

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Instituto Ecuatoriano de Enfermedades Digestivas (IECED) Gastroclinica SA

    Guayaquil, Guayas, Ecuador · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.